Taken together, our study revealed that the LCAT1-IGF2BP2-CDC6 axis has oncogenic activity and may serve as a potential therapeutic target as well as a prognostic biomarker for lung cancer. The gene discussed is IGF2BP2; the disease is lung cancer.